AstraZeneca PLC (FRA:ZEG)
Germany
· Delayed Price · Currency is EUR 127.95
+0.80 (0.63%)
At close: Jun 6, 2025, 10:00 PM CET
AstraZeneca Revenue
AstraZeneca had revenue of $13.59B USD in the quarter ending March 31, 2025, with 7.17% growth. This brings the company's revenue in the last twelve months to $54.98B, up 15.48% year-over-year. In the year 2024, AstraZeneca had annual revenue of $54.07B with 18.03% growth.
Revenue (ttm)
$54.98B
Revenue Growth
+15.48%
P/S Ratio
3.90
Revenue / Employee
$583.05K
Employees
94,300
Market Cap
198.58B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 54.07B | 8.26B | 18.03% |
| Dec 31, 2023 | 45.81B | 1.46B | 3.29% |
| Dec 31, 2022 | 44.35B | 6.93B | 18.53% |
| Dec 31, 2021 | 37.42B | 10.80B | 40.58% |
| Dec 31, 2020 | 26.62B | 2.23B | 9.16% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| SAP SE | 35.15B |
| Siemens Aktiengesellschaft | 77.82B |
| Deutsche Telekom AG | 120.25B |
| Allianz SE | 107.35B |
| Rheinmetall AG | 10.48B |
| Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 61.84B |
| Siemens Energy AG | 37.44B |
| Siemens Healthineers AG | 23.14B |
AstraZeneca News
- 1 day ago - AstraZeneca: Fascinating Company With Lofty Ambitions - Just Not A Buy Yet - Seeking Alpha
- 2 days ago - AstraZeneca’s £1 Billion Cambridge Hub Fuels UK Biotech Surge - ABC Money
- 5 days ago - Healthy Returns: AstraZeneca, Pfizer, Gilead and other drugmakers release promising cancer drug data at ASCO - CNBC
- 6 days ago - AstraZeneca says Enhertu, Perjeta combo cuts death risk in breast cancer - Seeking Alpha
- 6 days ago - AstraZeneca CEO on breast cancer drug trial: This is the future of cancer treatment - CNBC
- 6 days ago - How AstraZeneca Is Playing Its Cancer Cards To Become An $80 Billion Pharma - Investor's Business Daily
- 6 days ago - ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab reduced the risk of disease progression or death by 44% vs. THP as 1st-line therapy in patients with HER2-positive metastatic breast cancer in DESTINY-Breast09 Phase III trial - Benzinga
- 6 days ago - ENHERTU® Plus Pertuzumab Reduced the Risk of Disease Progression or Death by 44% Versus THP as First-Line Therapy in Patients with HER2 Positive Metastatic Breast Cancer in DESTINY-Breast09 Phase 3 Trial - Benzinga